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and reproduction in any medium, provided the original wIntestinal pathogens use the host’s excessive inflammatory cytokine response,
designed to eliminate dangerous bacteria, to disrupt epithelial gut wall integrity
and promote their tissue invasion. We sought to develop a non-antibiotic-based
approach to prevent this injury. Molecular docking studies suggested that
glycosylated dendrimers block the TLR4-MD-2-LPS complex, and a 13.6 kDa
polyamidoamine (PAMAM) dendrimer glucosamine (DG) reduced the induction
of human monocyte interleukin (IL)-6 by Gram-negative bacteria. In a rabbit
model of shigellosis, PAMAM-DG prevented epithelial gut wall damage and
intestinal villous destruction, reduced local IL-6 and IL-8 expression, and mini-
mized bacterial invasion. Computational modelling studies identified a 3.3 kDa
polypropyletherimine (PETIM)-DG as the smallest likely bioactive molecule. In
human monocytes, high purity PETIM-DG potently inhibited Shigella Lipid A-
induced IL-6 expression. In rabbits, PETIM-DG prevented Shigella-induced epi-
thelial gut wall damage, reduced local IL-6 and IL-8 expression, and minimized
bacterial invasion. There was no change in b-defensin, IL-10, interferon-b,
transforming growth factor-b, CD3 or FoxP3 expression. Small and orally deliv-
ered DG could be useful for preventing gut wall tissue damage in a wide spectrum
of infectious diarrhoeal diseases.INTRODUCTION
Infection with just 100 Shigella bacilli is sufficient to cause a
severe inflammatory bloody diarrhoea that affects 165 million
people worldwide and leads to >1 million deaths annually
(Kosek et al, 2010). Vaccine development is impaired by theImmunity, Imperial
ad, London, UK
Mole´culaire & Unite´
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ercial License (CC BY-NC 3
ork is properly cited and isantigenic diversity of the O-antigen of Shigella lipopolysacchar-
ide (LPS), and antibiotics do not prevent the pathogen-induced
and cytokine-mediated tissue injury. This has led to increasing
interest in modulating the host’s intestinal immune response
to enteric pathogens (Arpia et al, 2011; Bruckner & Finlay,
2011), which is characterized by an early cytokine-mediated
inflammatory response (Abreu, 2010; Ashida et al, 2011). The
pathogen-induced tissue injury is mediated, in part, by the
TLR4-MD-2-LPS complex (Ohto et al, 2007, 2012; Park et al,
2009), and shigellosis provides a well-defined in vivo model for
studying such damage (Perdomo et al, 1994; Raqib et al, 1995;
Schnupf & Sansonetti, 2012; Singer & Sansonetti, 2004). Both
Shigella and Salmonella can also activate Type III secretory
systems (TTSS) to enhance their gut wall invasion (Konradt
et al, 2011). A prompt macrophage TLR4-MD-2-LPS complex-
mediated cytokine response destroys pathogenic bacteria even if
the bystander cost is severe host organ tissue damage.s is an open access article under
.0), which permits use, distribution
not used for commercial purposes. EMBO Mol Med (2012) 4, 866–881
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sequential processes to make branched symmetrical molecules
(Hourani & Kakkar, 2010; Menjoge et al, 2010). Anionic
dendrimers have physico-chemical properties that are similar to
small molecule drugs, exist at physiological pH as zwitterions,
are not toxic or immunogenic, and preferentially accumulate in
tissues containing inflammatory cells (Kannan et al, 2012; Malik
et al, 2000). Previous studies showed that a combination of
dendrimer glucosamine (DG) and dendrimer glucosamine 6-
sulphate prevented scar tissue formation (Shaunak et al, 2004).
Molecular modelling studies also suggested that partial surface
glycosylation of divergently synthesized anionic dendrimers
confers physico-chemical properties that enable co-operative
electrostatic interactions with MD-2 in the TLR4-MD-2-LPS
complex (Barata et al, 2011a,b).
The additional finding that azabisphosphonate-capped den-
drimers selectively target monocytes and can also suppress pro-
inflammatory cytokines in mice with inflammatory arthritis
(Hayder et al, 2011) led us to translate our mechanistic
observations into a new dendrimer-based molecule. Our aim
was to create chemically well-defined molecules that would be
highly bioactive against the cytokine-mediated epithelial gut
wall damage that occurs in a wide spectrum of inflammatory
intestinal pathogen-mediated diarrhoeas (Vaisman et al, 2003).
Our plan for achieving this aim was to: (i) obtain in vitro and
in vivo biological proof-of-principle data with a large and
commercially available polyamidoamine (PAMAM) dendrimer
that we could glycosylate; (ii) identify and make a novel, much
smaller and simpler glycosylated dendrimer that had better in
vitro and in vivo bioactivity over a longer period of time.RESULTS
In vitro studies of PAMAM-DG with LPS and E. coli
We started with an UPLC (ultraperformance liquid chromato-
graphy)-purified 11.5kDa diaminobutane core PAMAM dendri-
mer (PAMAM-D) with 64 peripheral carboxylic acids to which
nine surface glucosamine molecules were covalently conjugated
(Shaunak et al, 2004 and Supporting Information Fig S1A and B).
PAMAM-DG had no antibacterial activity at 5mg/ml against the
Gram-negative Enterobacteriaceae Escherichia coli (Supporting
Information Fig S2). We used E. coli for some of the initial
experiments because Shigella belongs to the E. coli species, and its
Lipid A (a 1,40-bis-phosphorylated diglucosamine backbone to
which variable lengths and numbers of acyl chains are covalently
linked that anchors LPS to the outer membrane of Gram-negative
bacteria) is identical to that of Shigella (Lindberg et al, 1991).
When endotoxin free [<0.06 endotoxin units (EU)/ml, which is
the EU standard for water for injection] PAMAM-DGwas added to
primary humanmonocytes before addingE. coli at amultiplicity of
infection of 5, there was a 1923-fold reduction in interleukin (IL)-6
messenger RNA (mRNA) expression with a mean reduction of
103 32-fold in IL-8 (CXCL-8), tumour-necrosis factor (TNF)-a,
IL-1b, chemokine (C-C motif) ligand 3 (CCL3) (MIP-1a) and
chemokine (C-C motif) ligand 4 (CCL4) (MIP-1b) mRNA
expression (Fig 1A). The mRNA ED50 (PAMAM-DG concentrationEMBO Mol Med (2012) 4, 866–881that reduced mRNA expression by 50% compared to the
bacterial positive control) was 200 15mg/ml (15mM) and
the protein ED50 was 20 2mg/ml (1.5mM). When bacteria
were added to primary human monocytes 30min before the
PAMAM-DG, a 325-fold reduction in IL-6 expression with a
mean reduction of 27 6-fold in IL-8, TNF-a, IL-1b, CCL3 and
CCL4 expression was still seen (Fig 1B). These results show that
PAMAM-DG inhibited E. coli-induced cytokine responses in
human monocytes.
Polyamidoamine-dendrimer glucosamine competed partially
with an anti-TLR4 antibody (HTA125) on human monocytes
(Fig 1C). We had previously shown that there was reversibility
of the antagonist activity of PAMAM-DG on the induction of
human monocyte cytokines by LPS and that glucosamine and
the PAMAM dendrimer, when used alone, had no effect on
LPS-induced cytokine responses (Shaunak et al, 2004). PAMAM
dendrimer glucosamine 6-sulphate and PAMAM dendrimer
glucosamine 6-phosphate were also synthesized by conjugating
glucosamine 6-sulphate and glucosamine 6-phosphate, respec-
tively, to the PAMAM dendrimer using N-(3-dimethylamino-
propyl)-N0-ethylcarbodiimide hydrochloride (EDCI) and the
conjugation chemistry previously described (Shaunak et al, 2004;
Sam et al, 2010). Neither the sulphated nor the phosphorylated
PAMAM-DG had any effect on LPS-induced cytokine responses
in human monocytes (Supporting Information Fig S3).
In vitro studies of PAMAM-DG with LPS and Shigella
Polyamidoamine-dendrimer glucosamine had no antibacterial
activity against the Gram-negative Enterobacteriaceae Shigella
flexneri at 7mg/ml (Supporting Information Fig S4). The relative
contribution of the O-antigen and Lipid A to PAMAM-DG’s
bioactivity was determined by constructing genetically engi-
neered strains of S. flexneri that express structurally defined
modifications of LPS; gtrA has shorter O-chains and waaL
expresses an endotoxin component of LPS that binds only to
MD-2 (Molinaro et al, 2008; Rallabhandi et al, 2008; West et al,
2005). Endotoxin-free PAMAM-DG inhibited the induction of
IL-6, IL-8 and TNF-a in human monocytes by: (i) ultrapure
Shigella LPS and by wild type S. flexneri (M90T strain at a
multiplicity of infection of 10; Fig 1D); (ii) ultrapure LPS-gtrA
and the genetically engineered strain gtrA (Fig 1E); (iii)
ultrapure LPS-waaL and the genetically engineered strain waaL
(Fig 1F). The percentage inhibition of LPS-induced IL-6, IL-8 and
TNF-a in human monocytes by PAMAM-DG ranged from 80–
99.8% and it was greatest for IL-6 at 97.5–99.8%. Taken
together, these results suggested that DG was competing with
the Lipid A moiety of LPS for MD-2 rather than with the
oligosaccharides of LPS.
Reductionist molecular modelling studies
The large size (13.6 kDa) of the divergently synthesized and
glycosylated PAMAM dendrimer made it difficult to affordably
scale-up its synthesis and development. A search was therefore
undertaken for a next generation and divergently synthesized
dendrimer that was a smaller and simpler dendritic structure
using a molecular modelling-based approach and our recently
described design principles (Barata et al, 2011c). A combination 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 867
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Figure 1. In vitro cellular bioactivity of PAMAM-DG.
A. IL-6, IL-8 (CXCL-8), TNF-a, IL-1b, CCL3 (MIP-1a) and CCL4 (MIP-1b) mRNA levels were reduced (p< 0.0001) when PAMAM-DG (200mg/ml) was added to
human monocytes 30 min before E. coli. Pooled data (n¼9) shown as mean sem.
B. IL-6, IL-8, TNF-a, IL-1b, CCL3 and CCL4 mRNA levels were reduced (p<0.0001) when E. coli were added to human monocytes 30 min before PAMAM-DG
(200mg/ml). Pooled data (n¼ 9) shown as mean sem.
C. Preincubation of human monocytes with PAMAM-DG (200mg/ml) for 1 h reduced anti-TLR4 antibody binding by 35 7%. Pooled data: n¼8.
D–F. Preincubation of human monocytes with PAMAM-DG (200mg/ml) for 1 h inhibited the induction of IL-6, IL-8 and TNF-a in human monocytes by: (i) ultrapure
Shigella LPS and wild type S. flexneri (Sf; M90T strain) (D); (ii) ultrapure LPS-gtrA (shorter O-chains) and the genetically engineered strain gtrA (E); (iii)
ultrapure LPS-waaL (endotoxin component of LPS that binds only to MD-2) and the genetically engineered strain waaL (F). D¼1.660.55%. Pooled data
(n¼ 3) shown as mean sem. p< 0.0001; p values determined using a two-tailed Mann–Whitney test.
868of modelling and experimental studies suggested that PAMAM-
DG’s flexibility, surface glucosamine cluster density, electro-
static charge and hydrophilicity could be reproduced in an
anionic PETIM dendrimer (Fig 2A) with just 12 peripheral
carboxylic acids and four surface glucosamine molecules (MWt
3311Da; Fig 2B). Molecular dynamics simulations demon-
strated that this PETIM-DG exhibited the same flexibility as
PAMAM-DG with root mean square deviations for atomic
positions of 10 and 11 A˚, respectively. Its hydrophilic surface
(Fig 2C) and interpolated surface charges [neutral with areas of
well separated negative charges (Fig 2D)] closely resembled
PAMAM-DG.
Moreover, (i) the human MD-2 binding sites of PAMAM-DG
and PETIM-DG shared a common three residue interface
(Human/rabbit MD-2: R96K;Y102Y;S118P), and (ii) both
PAMAM-DG and PETIM-DG interfered with: (i) the primary
electrostatic binding of the 40-phosphate on the diglucosamine of
the Lipid A of LPS to Ser118 on MD-2, and (ii) with the secondary
binding of TLR4 to Tyr102 on MD-2 (Barata et al, 2011b). These
molecular modelling observations provided an explanation for
the bioactivity of DG. They were also consistent with the recent
finding that re-orientation of the aromatic side chain of Phe126 in 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.MD-2 is initiated by the binding of the fatty acyl chains of the
Lipid A of LPS to MD-2’s hydrophobic cavity, and that this is
followed by the binding of the MD-2-LPS complex to TLR4 and
TLR4-MD-2-LPS receptor complex formation (Yu et al, 2012).
PETIM dendrimer synthetic studies
Polypropyletherimine-(COOH)16 dendrimer containing ether
linkages, tertiary amine branching sites and n-propyl spacer
groups was chemically synthesized at the 15 g scale with
divergent dendrimer growth occurring through iterativeMichael
additions and functional group reductions (Jayamurugan &
Jayaraman, 2006; Krishna and Jayaraman, 2003). The purity of
the reagents used and of the alcohol, nitrile, amine and ester
intermediates formed was >95% as determined by high
performance liquid chromatography-charged aerosol detection
(HPLC-CAD). PETIM-(COOH)16 dendritic identity was con-
firmed by matrix-assisted laser desorption/ionization–time-of-
flight mass spectrometry (MALDI-TOF-MS; MWt¼ 2665Da;
Fig 3A) and NMR (nuclear magnetic resonance) spectroscopy
(Fig 3B). Purity by HPLC-CAD was 97% (Fig 3C). PETIM-
(COOH)16 dendrimer has been shown previously not to be toxic
in vivo (Jain et al, 2010).EMBO Mol Med (2012) 4, 866–881
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Figure 2. Structures for PETIM-(COOH)16 and PETIM-DG.
A. Anionic PETIM-(COOH)16 dendrimer.
B. PETIM-DG.
C. Hydrophilic (pale blue) and hydrophobic (brown) surfaces of PETIM-DG.
D. Charge surfaces for PETIM-DG with four surface glucosamines; red is negative surface charge and blue is positive surface charge.The high purity PETIM-(COOH)16 dendrimer was then partially
glycosylated with D-(þ)-glucosamine using EDCI, and complemen-
tary analytical techniques used to define its skeletal, generational
and substitutional components as previously described (Barata
et al, 2011c; Lalwani et al, 2009a,b; Sam et al, 2010; Shaunak et al,
2004). A structural and quantitative NMR analysis showed 4 amide
bond-conjugated surface glucosamines per dendrimer (Fig 3D–F
and Supporting Information Fig S5). Purity by HPLC-CAD and
HPLC-UV (Fig 3G and Supporting Information Figs S6–S8) and
capillary electrophoresis (CE; Fig 3H) was 97.2%.
Stability studies showed that PETIM-DG dissolved in water
was chemically stable with no loss of bioactivity after storage at
48C for 9 months, 378C/100% humidity for 42 days, and heating
to 708C for 1 h (Supporting Information Fig S9). In addition, no
in vivo toxicity was seen in CD-1 mice that were clinicallyEMBO Mol Med (2012) 4, 866–881observed for 24 h after a single oral dosing of PETIM-DG by
gastric lavage (n¼ 16) or a single intraperitoneal dosing (n¼ 16)
over the dose range 35–175mg/kg (unpublished observation).
In vitro studies of PETIM-DG with LPS
In vitro, PETIM-(COOH)16 dendrimer did not block LPS-induced
cytokine responses (Supporting Information Fig S9A). Endo-
toxin-free (<0.06 EU/ml) PETIM-DG at 600mg/ml was not toxic
to cells in whole human blood when cultured at 378C for 48 h
and then analyzed by Coulter flow cytometry for erythrocytes,
neutrophils, lymphocytes, monocytes, eosinophils, basophils
and platelets (Supporting Information Fig S10). TNF-a release
from purified human CD3þ T-lymphocytes was <10 pg/ml (EIA
limit of assay detection) and did not change when PETIM-DG
was added (unpublished observation). 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 869
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Figure 3. MS, NMR, HPLC and CE chemical analytics for PETIM-(COOH)16 and PETIM-DG.
A. MALDI-TOF-MS of PETIM-(COOH)16 dendrimer (MþH)þ¼ 2666 Da.
B. 1D 1H NMR (100% D2O) of PETIM-(COOH)16 dendrimer.
C. HPLC-CAD of PETIM-(COOH)16 dendrimer.
D. 1D 1H NMR (100% D2O) of PETIM-DG.
Residual N-acylurea and N-(3-dimethylaminopropyl)-N0-ethylurea (EDU). See also Supporting Information Fig S5.
E. Amide region from 2D 1H–1H ROESY (rotating-frame Overhauser effect spectroscopy; 90:10 H2O:D2O) of PETIM-DG showing intermolecular ROE peaks from
amide proton to anomeric proton, proximal sugar ring protons, and across the peptide bond (NH–CO–CH2).
F. a and b anomeric protons of the C1 carbon of glucosamine from 2D 1H–13C HSQC (heteronuclear single quantum correlation) NMR (100% D2O). Integrals are
relative to resolved peaks for 52 CH2–CH2–CH2 protons.
G. HPLC-UV of PETIM-DG. See also Supporting Information Figs S6–S8.
H. CE (capillary electrophoresis) at pH 8.55 of PETIM-DG, and of 3 of 11 fractions collected and analyzed from the HPLC peak shown in (G). The main PETIM-DG
peak and the main peak in all of the three fractions shown in (G) (fractions B, C and D) are aligned at 2.00 min; the water peak in each sample was used to align
all four CE chromatograms.
870Endotoxin-free (<0.06 EU/ml) PETIM-DG was a dose-depen-
dent antagonist of both ultra-pure Salmonella minnesota LPS
(Fig 4A—left hand of panel) and of synthetic Lipid A (Fig 4A—
right hand of panel) in HEK293 TLR4-MD-2-CD14-transfected
cells with an mRNA ED50 (PETIM-DG concentration that
reduced the S. minnesota LPS and synthetic Lipid A positive 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.controls by 50%) of 60 5mg/ml (4.5mM). PETIM-DG had no
effect on the IL-8 response in HEK293 TLR3-transfected cells
using poly(I:C) as the agonist (Fig 4B).
In TLR4-MD-2-CD14-transfected HEK293 cells, ultrapure
S. minnesota LPS (25 ng/ml) is an MD-2 agonist, and LPS-RS
(2500 ng/ml), which is the diphosphoryl Lipid A of RhodobacterEMBO Mol Med (2012) 4, 866–881
www.embomolmed.org Research Article
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Figure 4. In vitro cellular bioactivity of PETIM-DG.
A. PETIM-DG inhibited S. minnesota LPS- and synthetic Lipid A-induced IL-8 mRNA expression in HEK293 TLR4-MD-2-CD14-transfected cells with an mRNA
ED50¼60 5mg/ml (4.5mM). Pooled data (n¼ 6) shown as mean sem on a log10 scale. p Values determined using a two-tailed Mann–Whitney test.
B. PETIM-DG had no effect on poly(I:C)-induced IL-8 mRNA and protein in HEK293 TLR3-transfected cells at 24 h. Pooled data (n¼3) shown as mean sem on a
log10 scale. p Values determined using a two-tailed Mann–Whitney test.
C. Human monocytes were cultured with (i) ultrapure S. minnesota LPS (25 ng/ml), (ii) LPS-RS which is the diphosphoryl Lipid A of R. sphaeroides (2.5mg/ml), (iii)
LPS-RS (2.5mg/ml for 1 h) followed by LPS (25 ng/ml), (iv) PAMAM-DG (200mg/ml for 1 h) followed by LPS (25 ng/ml) and (v) PETIM-DG (200mg/ml for 1 h)
followed by LPS (25 ng/ml). Three hours later, the cells were harvested and RNA extracted. LPS-RS was an antagonist for TNF-a and IL-6 but an agonist for
IL-8 mRNA expression. PAMAM-DG and PETIM-DG were antagonists for TNF-a, IL-6 and IL-8. Pooled data (n¼3) shown as percentage mean sem of the
ultrapure S. minnesota LPS response which was defined as 100% for each cytokine.
D–F. Preincubation of human monocytes with PETIM-DG (100mg/ml) for 1 h inhibited the induction of IL-6, IL-8 and TNF-a in human monocytes by: (i) ultrapure
Shigella LPS and wild type S. flexneri (Sf; M90T strain) (D); (ii) ultrapure LPS-gtrA (shorter O-chains) and the genetically engineered strain gtrA (E);
(iii) ultrapure LPS-waaL (endotoxin component of LPS that binds only to MD-2) and the genetically engineered strain waaL (F). D¼ 0.0290.007%.
Pooled data (n¼ 3) shown as mean sem. p< 0.0001; p values determined using a two-tailed Mann–Whitney test.sphaeroides, has been reported to be an MD-2 antagonist
(Kutuzova et al, 2001; Takayama et al, 1989). We compared the
bioactivity of LPS-RS with that of LPS in human monocytes.
LPS-RS (used at a 100-fold excess as recommended by the
supplier Invivogen) reduced LPS-induced TNF-a expression
(92 3% of the LPS-induced control) and IL-6 expression
(82 2% of the LPS-induced control; Fig 4C). Surprisingly,
in the case of IL-8, LPS-RS acted as an agonist (Fig 4C). This was
in contrast to both endotoxin-free PAMAM-DG (200mg/ml)
and PETIM-DG (100mg/ml), which consistently reduced
LPS-induced TNF-a, IL-6 and IL-8 expression (Fig 4C). Taken
together, these results showed that PAMAM-DG and PETIM-DG
were better antagonists of MD-2 for TNF-a, IL-6 and IL-8 than
LPS-RS in primary human monocytes.
When intestinal epithelial Caco-2 cells were used [function-
ally intact for both TLR4 and intracellular LPS signalling, but
without MD-2 (Abreu et al, 2001)], neither LPS nor endotoxin-EMBO Mol Med (2012) 4, 866–881free PETIM-DG had an effect on cytokine responses (Supporting
Information Fig S11). Shigella is inefficient at entering gut
columnar epithelial cells and does not activate cytosolic sensors
and Nod-mediated signalling (Coron et al, 2009). Thus, the
absence of enterocyte cell surface MD-2 explained the lack of
effect of both LPS and DG. These in vitro biological studies
showed that DG was an antagonist of MD-2-Lipid A mediated
cytokine responses in human monocytes.
In vitro studies of PETIM-DG with bacteria
Polypropyletherimine-DG had no antibacterial activity at
5mg/ml against E. coli (Supporting Information Fig S12). It
inhibited the induction of IL-6, IL-8 and TNF-a in human
monocytes by: (i) ultrapure Shigella LPS and wild-type
S. flexneri (M90T strain at a multiplicity of infection of 10;
Fig 4D); (ii) ultrapure LPS-gtrA and the genetically engineered
strain gtrA (Fig 4E); (iii) ultrapure LPS-waaL and the genetically 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 871
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872engineered strain waaL (Fig 4F). The percentage inhibition of
LPS-induced IL-6, IL-8 and TNF-a expression by endotoxin-free
PETIM-DG in human monocytes ranged from 85–99.97% and it
was greatest for IL-6 at 97.5–99.97%. The mRNA ED50 (PETIM-
DG concentration that reduced the bacterial positive control by
50%) was 100 7mg/ml and the protein ED50 was 10 1mg/ml
(3.3mM). Notably, PETIM-DG was 57-fold more potent at
suppressing Shigella waaLmutant LPS (i.e. Lipid A— endotoxin
component of LPS that binds only to MD-2)-induced human
monocyte IL-6 than PAMAM-DG (Figs 1F and 4F). Taken
together, these results suggest that DG is competing with
the Lipid A moiety of LPS for MD-2 rather than with the
oligosaccharides of LPS, and that, in vitro, PETIM-DG is a better
antagonist than PAMAM-DG of the MD-2-Lipid A interaction in
human monocytes. 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.Rabbit model of shigellosis and quantitative RT-PCR
transcriptional gene analysis
As the human MD-2 amino acid residues binding LPS and the
proposed binding sites for PAMAM-DG (Barata et al, 2011b)
in small animals are most conserved in rabbit (Human/rabbit
MD-2: K91K;R96K;S98S;Y102Y;R106R;K109K;T112T;N114N;
T116T;S118P), a rabbit intestinal loop model of shigellosis
was used to determine the bioactivity of PAMAM-DG
(Perdomo et al, 1994; Raqib et al, 1995; Singer & Sansonetti,
2004). Rabbits are phylogenetically, anatomically and physio-
logically more closely related to primates than rodents, and,
in many cases, lead to better modelling of human disease states.
In the context of shigellosis, the well-defined histopathology
of this animal model (Fig 5A and B) mirrors the clinical
observation that the IL-6- and IL-8-mediated inflammatoryFigure 5. Histology of PAMAM-DG’s and
PETIM-DG’s in vivo bioactivity in the rabbit
model of shigellosis. Sections stained with H&E.
Scale bars¼50mm.
A. Gut intestinal villi after infection with 107 wild
type S. flexneri and treatment with intraluminal
saline control. There was complete loss of surface
columnar epithelium and intestinal villous
destruction (de) with crypt goblet cell depletion.
Sub-mucosal edema and blood vessel thrombosis
(t) were associated with a marked neutrophil,
lymphocyte and monocyte infiltrate in the gut
lamina propria (c). Result from 1 of 4 experiments
shown.
B. Peyer’s patches after infection with 107 wild type
S. flexneri and treatment with intraluminal saline
control. The Peyer’s patches (p) were preserved
but their specialized epithelium was lost (de).
Result from 1 of 4 experiments shown.
C. Gut intestinal villi after infection with S. flexneri
and treatment with PAMAM-DG. Mucus (m) was
present, and the columnar epithelium (e) and
intestinal villi (v) were both intact. This protected
the lamina propria (a) from any damage. Result
from 1 of 6 experiments shown.
D. Peyer’s patches after infection with S. flexneri and
treatment with PAMAM-DG. The columnar epi-
thelium (e) and intestinal villi (v) were both
intact. This protected the Peyer’s patches (p) from
any damage. Result from 1 of 6 experiments
shown.
E. Gut intestinal villi after infection with S. flexneri
and treatment with PETIM-DG. Mucus (m) was
present, and the columnar epithelium (e) and
intestinal villi (v) were both intact. This protected
the lamina propria (a) from any damage. Result
from 1 of 6 experiments shown.
F. Peyer’s patches after infection with S. flexneri and
treatment with PETIM-DG. The columnar epi-
thelium (e) and intestinal villi (v) were both
intact. This protected the Peyer’s patches (p) from
any damage. Result from 1 of 6 experiments
shown.
EMBO Mol Med (2012) 4, 866–881
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Islam et al, 1994; Schnupf & Sansonetti, 2012; Sperandio et al,
2008).
However, the limited availability of enzyme immuno-assay
reagents for rabbit cytokines and chemokines and for the
immuno-histochemistry of both cells and tissue sections means
that conventional histological examination remains the gold
standard for analyzing the rabbit’s immune response. Also
rabbit microarrays are not available. It is in this context that we
have used quantitative polymerase chain reaction (after reverse
transcription) (RT-PCR) as a sensitive and rapidmeans bywhich
to monitor the spectrum of the host immune response. While
quantitative PCR lacks the large-scale throughput of micro-
arrays, it is considered to be the gold standard for gene
expression analysis because of its ease of use, high detection
sensitivity and wide linear dynamic range. The rabbit ileal loop
model of shigellosis is accurate both morphologically and with
respect to transcriptional gene activation during the course of an
infection (Schnupf & Sansonetti, 2012).
For our RT-PCR assays, we designed and created human and
rabbit multi-gene quantification plasmids as standards and used
SYBR Green hot-start PCR-based amplification rather than a
fluorescent probe-based detection system because the cost
differential for multiple gene analysis in many samples can be
considerable. Hypoxanthine phosphoribosyltransferase (HPRT)
was chosen as the reference ‘housekeeping’ gene because it is a
reliable medium-to-low abundance mRNA transcript as pre-
viously described (Corware et al, 2011; Shaunak et al, 2004).
The principle advantage of using a multi-gene plasmid-based
quantification standard rather than a comparative DCt or a
D-DCtmethod was that our approach did not depend upon equal
amplification efficiencies for both the target and the ‘house-
keeping’ HPRT reference gene. In addition, the assay reliably
and reproducibly generates real mRNA copy numbers that can
be directly correlated with the amount of starting RNA or cell
number. This enables a considerably more accurate cross
comparison of the mRNA levels of different chemokines and
cytokines across multiple experiments.
Bioactivity of a large PAMAM-DG molecule in shigellosis
The in vivo studies started with the intraperitoneal administra-
tion of 10mg/ml of endotoxin-free (<0.06 EU/ml) PAMAM-DG
(20mg/kg) dissolved in isotonic saline to rabbits during the
surgical procedure to create and infect the ligated ileal loops
with S. flexneri. This initial experiment showed that 20mg/kg of
intraperitoneal PAMAM-DG was bioactive in reducing gut wall
tissue injury and in reducing IL-6 expression in Peyer’s patches
(Supporting Information Fig S13). The intraperitoneal route of
administration was not studied further because one of our key
aimswas tomake an orally bioavailable and bioactive molecule.
Studies in rats have previously shown that 96% of an orally
administered tritiated dendrimer with 16 peripheral groups and
a diameter of 2.5 nm was retained in the gut (Florence et al,
2000). The peak level of tritiated dendrimer in the small and
large bowel was seen at 6 h with <1% remaining in the gut at
24 h (Sakthivel et al, 1999). These observations led us to
conclude that in our rabbit model of shigellosis, administrationEMBO Mol Med (2012) 4, 866–881of DG into the ligated ileal loops would mean that most of it
would remain in the gut lumen.
Wild-type S. flexneri (M90T strain, 107 bacteria/loop) and
endotoxin-free PAMAM-DG were administered into ligated ileal
loops with Peyer’s patches; i.e. aggregated lymphoid follicles
that are separated from the gut lumen by a specialized follicle-
associated epithelium. In the mouse Peyer’s patch, 60% of
the cells are B-cells (B220þ), 25% are T-cells (CD3þ), 10% are
dendritric cells (CD11cþ), 4.5% are macrophages (F4/80þ) and
neutrophils (Ly-6Gþ), and 0.5% are CD3þCD4þFoxP3þ T
regulatory (Treg) cells (Barreau et al, 2007). Typically, four
ligated loops with Peyer’s patches were created in each rabbit.
Our studies were focused on Peyer’s patches because of the
intimate association of their overlying epithelium with patho-
genic bacteria in the earliest stages of an infectious diarrhoeal
disease (Inman and Cantey, 1984; Takeuchi, 1967; Takeuchi
et al, 1968, 1978). The animal infection experiments with
PAMAM-DG were undertaken for a 12 h period.
In rabbits receiving 5mg/loop of endotoxin-free (<0.06EU/ml)
PAMAM-DG, there was minimal damage to surface epithelium
and intestinal villi at 12 h, and crypt goblet cells were preserved
(Fig 5C and D). This PAMAM-DG-mediated protection of
columnar epithelium was associated with a 282-fold reduction
in IL-6 (Fig 6A) and a 14-fold reduction in IL-8 expression in
Peyer’s patches (Fig 6B). At 12 h, TNF-a expression did not
change when compared to both healthy rabbits and infected
untreated rabbits (Fig 6C). IL-10 (anti-inflammatory cytokine)
did not change when compared to infected untreated rabbits
at 12 h (Fig 6D). Interferon-b (TRIF-dependent mediator of
dendritic cell maturation) expression did not change signifi-
cantly in infected treated rabbits (5430 760 mRNA/105 HPRT)
compared to infected untreated rabbits (3700 810 mRNA/105
HPRT; n¼ 3; p¼ 0.06). b-defensin (an epithelial cell anti-
microbial peptide) expression also did not change in infected
treated rabbits (3570 100 mRNA/105 HPRT) compared to
infected untreated rabbits (3940 1040 mRNA/105 HPRT; n¼ 3;
p¼ 0.7). CD3þ mRNA expression increased threefold in infected
and PAMAM-DG-treated rabbits (1.53 0.11 106 copies of CD3
mRNA/105 HPRT) over infected untreated control rabbits [0.50
0.03 106 copies of CD3 mRNA/105 HPRT (n¼ 3; p¼ 0.01)].
No clinical toxicity, or macroscopic or microscopic organ
based tissue toxicity was seen in the rabbits (unpublished
observation). Although intestinal bacterial counts increased
from 107 to 5 108 colony forming units because PAMAM-DG
has no anti-bacterial activity (Supporting Information Figs S2
and S14), Peyer’s patch Shigella IcsA expression (an indicator of
bacterial gut wall invasion) fell by 82 8% in PAMAM-DG-
treated rabbits (5mg/loop) compared to infected untreated
animals (Supporting Information Fig S15). Gut tissue immuno-
histochemistry for Shigella LPS confirmed this large reduction in
bacterial gut wall invasion in rabbits treated with PAMAM-DG
(Supporting Information Fig S16).
Bioactivity of a small PETIM-DG molecule in shigellosis
The time period of animal infection with S. flexneri was
extended to 18 h in the PETIM-DG studies. These in vivo rabbit
studies showed that endotoxin-free (<0.06 EU/ml) PETIM-DG 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 873
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Figure 6. PAMAM-DG and PETIM-DG reduced IL-6 and IL-8 expression but not TNF-a or IL-10 expression in Peyer’s patches upon S. flexneri infection.
A. IL-6 mRNA levels increased during the course of a wild type S. flexneri (Sf) infection. This cytokine increase was reduced by 5 mg/loop of PAMAM-DG at 12 h and
by 0.5 mg/loop of PETIM-DG at 18 h. PAMAM-dendrimer (PAMAM-D) had no effect.
B. IL-8 mRNA levels increased during the course of a wild type S. flexneri (Sf) infection. This cytokine increase was reduced by 5 mg/loop of PAMAM-DG at 12 h and
by 0.5 mg/loop of PETIM-DG at 18 h. PAMAM-dendrimer (PAMAM-D) had no effect.
C. TNF-amRNA levels increased 3.2-fold at 18 h during the course of a wild-type S. flexneri infection. PAMAM-dendrimer, PAMAM-DG and PETIM-DG had no effect
on TNF-a mRNA levels compared to healthy control rabbits.
D. The infection-associated increase in IL-10 mRNA levels at 12 h was not reduced by PAMAM-DG. At 18 h, IL-10 mRNA had fallen to the healthy control
level in all groups. Pooled data (n¼ 4) shown as mean sem on a log10 scale. K¼ thousand, M¼million. p Values determined using a two-tailed
Mann–Whitney test.
874was bioactive against S. flexneri at 0.5mg/loop (600mg/kg)
with complete protection of gut surface columnar epithelial cells
and intestinal villi. Crypt goblet cell preservation suggested that
there was no loss of mucins (Fig 5E and F). In addition, there
was a 1653-fold reduction in IL-6 (Fig 6A) and a 238-fold
reduction in IL-8 expression (Fig 6B) in Peyer’s patches
compared to the untreated control. At 18 h, TNF-a expression
did not change when compared to healthy rabbits andwas lower
than in infected untreated rabbits (Fig 6C). IL-10 expression did
not change when compared to both healthy rabbits and infected
untreated rabbits at 18 h (Fig 6C). Interferon-b expression
did not change significantly in infected treated rabbits
(7400 3560 mRNA/105 HPRT) compared to healthy control 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.rabbits (3570 860 mRNA/105 HPRT; n¼ 3; p¼ 0.4), and
b-defensin expression also did not change significantly in
infected treated rabbits (18,000 1100 mRNA/105 HPRT)
compared to healthy control rabbits (12,400 860 mRNA/105
HPRT; n¼ 3; p¼ 0.3). The result for b-defensin is notable because
the antibacterial peptides LL-37 and human b-defensin-1 are
reduced in human shigellosis and it can take 60 days for them to
be restored in surface epithelial cells (Islam et al, 2001). Taken
together, these results suggest that PETIM-DGwas still bioactive
18 h after the onset of infection at a 2.5-fold (molar basis —
0.15mM/loop) to 10-fold (weight basis — 0.5mg/loop) lower
concentration than PAMAM-DG (molar basis — 0.38mM/loop;
weight basis — 5mg/loop). No clinical, or macroscopic orEMBO Mol Med (2012) 4, 866–881
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Figure 7. CD3, Fox P3, TGF-b and caspase-3 expression in Peyer’s patches.
A. CD3þ mRNA levels increased upon S. flexneri (Sf) infection at 18 h post-infection, and increased further upon infection and PETIM-DG treatment.
B. There was no change in FoxP3þ mRNA levels (an indicator of Treg cells) upon infection or with PETIM-DG treatment.
C. The 2.3-fold infection-associated increase in TGF-b mRNA levels was not affected by PETIM-DG.
D. Caspase-3 mRNA levels (an indicator of apoptosis) increased 3.7-fold with wild type S. flexneri (Sf) infection at 18 h. This increase was prevented by 0.5 mg/loop
of PETIM-DG. Pooled data (n¼3) shown as mean sem on a log10 scale. M¼million. p Values determined using a two-tailed Mann–Whitney test.microscopic organ based tissue toxicity was seen in PETIM-DG
treated rabbits (unpublished observation).
CD3þ mRNA expression increased significantly in infected
and PETIM-DG-treated rabbits over uninfected control rabbits
(13-fold), and slightly over infected untreated control rabbits
(2.7-fold; Fig 7A). Forkhead box P3 (FoxP3) expression was not
altered by either S. flexneri infection or by PETIM-DG treatment
(Fig 7B) while transforming growth factor-b (TGF-b) expression
increased 2.3-fold upon infection and was not altered by PETIM-
DG treatment (Fig 7C). Infiltration of the surface epithelium and
lamina propria by gdþ CD4þ and CD8þ T-cells occurs in human
shigellosis (Islam & Christensson, 2000; Raqib et al, 1994)
with CD3þCD4þFoxP3þ T regulatory (Treg) cells maintaining
gut tolerance by suppressing local antigen specific immune
responses to commensal bacteria (Sellge et al, 2010). In theEMBO Mol Med (2012) 4, 866–881steady state, Treg cells are dependent upon local dendritic cell-
and TGF-b-induced signals (Izcue et al, 2009), but when
proinflammatory cytokines increase, they switch to become
dependent upon monocyte/macrophage-derived IL-10 (Murai
et al, 2009; Unutmaz & Pulendran, 2009). Our results suggest
that DG alters the recently recognized balance between
cytokine-mediated tissue injury and T cell-mediated tolerance
in the gut (Ismail et al, 2009, 2011) so that epithelial gut wall
integrity is preserved and bacterial gut wall invasion is
minimized. This conclusion is also supported by the observation
that shigellosis-induced apoptosis of gut lamina propria CD3þ
T-cells, CD15þ granulocytes and CD56þ macrophages (Lembo-
Fazio et al, 2011; Raqib et al, 2002; Zychlinsky et al, 1996) was
prevented by PETIM-DG as measured by caspase-3 mRNA
expression (Fig 7D). 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 875
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Figure 8. Spleen cytokines. IL-6, IL-8, TNF-a, CCL4 and IL-10 mRNA
expression was lower in spleen than in Peyer’s patches at 18 h. The levels were
not affected by local administration of PETIM-DG into the ileal loops.
S. flexneri (Sf). Pooled data (n¼3) shown as mean sem on a log10 scale.
876Finally, there was no change in IL-6, IL-8, TNF-a, CCL4 or
IL-10 expression in the spleen (Fig 8). This confirmed the gut
localization of the host cytokine response to shigellosis.DISCUSSION
Our integration of modelling studies with biological experiments
led to a 75% reduction in the molecular weight of the DG
from 13.6 to 3.3 kDa and an increase in its purity to 97%. This
synthetic baby-bio (SBB; Barata et al, 2011b,c) prevented
the pathogen-induced and cytokine-mediated injury to gut
columnar epithelium and intestinal villi that is associated with
increased IL-6 and IL-8 expression in shigellosis. Complete
protection of the epithelial gut wall in rabbits by PETIM-DG at a
dose 0.5mg/loop (600mg/kg) prevented crypt goblet cell
depletion and submucosal edema, and also minimized bacterial
gut wall invasion. An illustration of the proposed mechanism
for epithelial gut wall damage in shigellosis and the protective
effect of DG is shown in Fig 9. In addition, PETIM-DG
did not interfere with endogenous anti-microbial peptides,
TRIF-dependent dendritic cell maturation or CD3 and FoxP3
expression. The shigellosis-induced increase in caspase-3 was
also prevented. This suggests that the key functions of IL-10 and
TGF-b in controlling TLR-mediated activation of antigen
presenting cells in the gut were not disrupted by PETIM-DG.
These animal model-based results are consistent with two
important clinical observations for intestinal diarrhoeal dis-
eases. The first is that severe shigellosis (i.e. hemolytic uremic
syndrome, thrombocytopenia and severe colitis >1 week) is
associated with elevated IL-6 rather than TNF-a (Harendra de
Silva et al, 1993). The second is that only acute invasive
bacterial enteritis in humans, such as that due to Shigella spp.,
enterohemorrhagic E. coli, Salmonella spp. and Campylobacter 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.spp. have been shown to be associated with increased IL-6 and,
to a lesser degree, IL-8 expression (Vaisman et al, 2003). In this
context, it is interesting to note that gut pathogens are often
found in very close proximity to the gut surface epithelium, a
position from which they can stimulate local pro-inflammatory
cytokine responses. Electron microscopy studies of the earliest
stages of S. flexneri, enterohemorrhagic E. coli and Salmonella
typhimurium infections have demonstrated the intimate nature
of this association between pathogenic bacteria and the
specialized epithelium overlying Peyer’s patches (Inman and
Cantey, 1984; Takeuchi, 1967; Takeuchi et al, 1968, 1978).
Our molecular modelling studies suggested that PETIM-DG’s
antagonist activity depended upon the formation of co-operative
electrostatic interactions with two key residues that line the
entrance to MD-2’s hydrophobic pocket; the first is Ser118 to
which the 40-phosphate on the diglucosamine of Lipid A binds,
and the second is Tyr102 to which TLR4 binds. The binding of
PETIM-DG to MD-2 blocks the entry of the acyl chains of the
Lipid A of LPS into MD-2’s hydrophobic pocket. This prevents
the formation of the primary MD-2-LPS complex and the
secondary TLR4-MD-2-LPS receptor complex. The b cup
topology of the lipid binding pocket of MD-2 reflects its need
to accommodate large and structurally diverse ligands. Such
promiscuity is an important evolutionary feature and reflects the
need for MD-2 to be able to recognize all of the diverse LPS
structures synthesized by individual species of Gram-negative
bacteria, and also the binding of those endogenous host derived
ligands that act as alert signals for tissue injury including enzyme
derived fragments of hyaluronan from injured extracellularmatrix
(Atala et al, 2010; O’Neill, 2005). In this context, we believe that
our studies have defined the first non-lipid based synthetic
antagonist of MD-2 using both molecular modelling studies and
animal model based studies of cytokine responses. Using a similar
approach, it should now be possible to computationally design
additional dendrimer based antagonists for other Toll-like
receptors. This could provide new opportunities for treating a
range of infectious, inflammatory and malignant diseases in
whose pathogenesis Toll-like receptors play an important role.
If our results are reproduced in non-human primates (the only
other natural host for shigellosis), small, well defined, cost-
effective and orally delivered glycosylated dendrimers could
become a useful new therapeutic addition for a spectrum of
other cytokine-mediated inflammatory diarrhoeas including
infection with enterohemorrhagic E. coli (Buchholz et al, 2011),
Salmonella sp. (Arpia et al, 2011), Campylobacter sp. (Rathinam
et al, 2009) and potentially even Clostridium difficile, which has
recently been shown to also engage TLR4 (Ryan et al, 2011).
Furthermore, this non-antibiotic-based approach to treating
infectious diarrhoeas is one to which pathogen resistance will
likely not arise. It also supports the growing recognition from
both human and animal studies that it is the pathogen-triggered
and IL-6-mediated gut cytokine storm that destroys epithelial
gut wall integrity, promotes bacterial tissue invasion, and leads
to severity of clinical disease seen. Our results suggest that
small and orally delivered glycosylated dendrimers could be
therapeutically useful for preventing gut wall tissue damage in a
wide spectrum of infectious diarrhoeal diseases.EMBO Mol Med (2012) 4, 866–881
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Figure 9. Illustration of the proposed mechanism for epithelial gut wall damage in shigellosis and the protective effect of DG.
A. In the normal and healthy state, local cytokine production in response to commensal gut bacteria protects epithelial cells and macrophages from apoptosis.
B. The initial host response to S. flexneri infection is increased local IL-6 and IL-8 with minimal bystander damage to epithelial gut wall integrity. This is a
physiologically appropriate response.
C. Severe infection leads to an excessive pathogen-triggered IL-6 and IL-8 gut cytokine storm that destroys the epithelial gut wall’s integrity. Bacterial invasion
follows with apoptosis of epithelial cells, neutrophils, lymphocytes, monocytes and tissue macrophages.
D. Treatment with DG alters the balance between cytokine mediated tissue injury and T-cell mediated tolerance so that epithelial gut wall integrity is preserved
and bacterial gut wall invasion is minimized.
EMBO Mol Med (2012) 4, 866–881  2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 877
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The paper explained
PROBLEM:
Intestinal pathogens cause life threatening diarrhoeas in
hundreds of millions of people worldwide. They use the host’s gut
cytokine storm and the associated tissue injury to promote their
tissue invasion. IL-6 and IL-8 are primarily responsible for the
severity of epithelial gut wall damage seen in both humans and
animals. This tissue injury is not prevented by antibiotic
treatment. We therefore sought a new molecule and approach by
which to prevent this acute cytokine-mediated damage to gut
epithelium.
RESULTS:
The TLR4-MD-2-LPS complex is involved in mediating this
pathogen-induced tissue damage, and shigellosis is a well-
defined disease model for its study. Chemically defined and high
purity DG-based molecules were synthesized and tested in vitro
and in vivo. A large (13.6 kDa) and small (3.3 kDa) DG molecule
prevented both epithelial gut wall damage and intestinal villous
destruction when given locally into the gut. This protection was
associated with reduced IL-6 and IL-8 in the Peyer’s patches; i.e.
gut associated lymphoid tissues. Taken together, this suggests
that treatment with DG alters the balance between cytokine
mediated tissue injury and T-cell mediated tolerance to preserve
epithelial gut wall integrity and minimize bacterial gut wall
invasion.
IMPACT:
With rapidly increasing bacterial virulence and antibiotic
resistance worldwide, small, well defined, cost-effective and
orally delivered glycosylated dendrimers could become a useful
new therapeutic addition for a wide spectrum of cytokine
mediated inflammatory diarrhoeas. They include infections with
Shigella spp., enterohemorrhagic E. coli, Salmonella sp., Campy-
lobacter sp., and potentially C. difficile. The non-antibiotic based
approach described here for treating infectious diarrhoeas
supports the recent and growing recognition that the pathogen-
triggered and local IL-6 cytokine storm destroys epithelial gut
wall integrity, promotes bacterial gut wall invasion, and leads to
severity of clinical disease seen. Small and orally delivered DG
could be therapeutically useful for preventing this tissue damage
in a wide spectrum of infectious diarrhoeal diseases.
878MATERIALS AND METHODS
Molecular modelling, chemical synthesis and analytical
studies
Longer molecular dynamics with explicit solvent and molecular docking
were performed as previously described (Barata et al, 2011a,b,c). The
anionic G3.5 PAMAM dendrimer (diaminobutane core) was synthesized
by Dendritic Nanotechnologies Michigan. PAMAM-(COONa)64 dendrimer:
1H NMR (500MHz, D2O, 303K): d 3.553.50 (br m, 65H), 3.383.34
(br m, 56H), 3.183.10 (br m, 120H), 3.053.00 (br m, 62H),
2.912.86 (br m, 123H), 2.722.67 (br m, 64H), 2.572.47 (br m,
244H), 1.56 (br s, 4H). 13C NMR (125MHz, D2O, 303K): d 179.5, 175.2,
174.6, 51.3, 50.3, 48.9, 48.8, 36.7, 35.6, 32.5.
The anionic G3 PETIM dendrimer was synthesized as previously
described with minor modifications (Jain et al, 2010; Jayamurugan &
Jayaraman, 2006; Krishna and Jayaraman, 2003). PETIM-
(COOH)1614HCl dendrimer: 1H NMR (500MHz, D2O, 303K): d
3.713.64 (m, 52H), 3.593.55 (m, 32H), 3.433.39 (m, 16H),
3.353.30 (m, 36H), 3.032.99 (m, 32H), 2.162.04 (m, 52H). 13C
NMR (125MHz, D2O, 303 K): d 174.1, 68.0, 67.7, 67.5, 52.3, 50.8,
50.7, 49.5, 28.4, 23.6, 23.5, 23.3.
D-(þ)-glucosamine (purity 99%) was conjugated to both the PAMAM
dendrimer’s carboxylic acid groups and the PETIM dendrimer’s
carboxylic acid groups using EDCI as previously described (Sam et al,
2010; Shaunak et al, 2004). PAMAM-DG: 1H NMR (500MHz, D2O,
303K): d 5.25 (d, J¼3.5Hz, 5H), 3.962.99 (m, 555H), 2.932.61
(m, 235H), 2.112.02 (m, 10H), 1.84 (br s, 4H), 1.241.19 (m, 15H).
PETIM-DG: 1H NMR (500MHz, D2O, 303K): d 5.265.23 (m, 3H),
3.963.04 (m, 218H), 2.932.88 (m, 30H), 2.692.66 (m, 14H), 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.2.181.90 (m, 64H), 1.271.19 (m, 8H), 1.11 (t, J¼7.4Hz, 2H). 13C
NMR (125MHz, D2O, 303 K): d 177.9, 177.7, 177.5, 174.2, 173.4,
172.5, 172.2, 172.0, 94.8, 90.8, 76.0, 73.9, 73.8, 71.7, 70.8, 70.2,
70.0, 67.7, 67.6, 67.4, 60.8, 60.7, 57.0, 56.7, 55.4, 55.0, 54.2, 54.1,
50.9, 50.8, 50.6, 49.7, 49.5, 49.4, 49.3, 42.9, 42.8, 41.7, 40.2, 37.3,
36.5, 35.9, 35.0, 30.7, 30.2, 30.1, 30.0, 29.5, 29.2, 25.0, 24.3, 23.6,
14.5, 13.6, 13.4.
The NMR-based analytical methods used for compound identity
included 1D 1H NMR in 100% D2O and 90:10 H2O:D2O, 2D
1H–13C
HSQC NMR and 2D 1H–1H ROESY NMR spectra (500/600/800MHz
Bruker). The MS based analytical methods used for compound identity
included MALDI-TOF-MS, trimethylsilyl gas chromatography–mass
spectrometry (TMS GC–MS), and esterification (methanolic-hydro-
chloric acid) of the peripheral carboxylic acids. HPLC with CAD and UV
detection at 214nm, as well as CE (pH 8.55–9.51) were used to
determine compound purity as previously described (Barata et al,
2011c; Lalwani et al, 2009a,b; Shaunak et al, 2004).
In vitro biology
Human monocytes (106/ml) were prepared and used as previously
described (Corware et al, 2011; Sabroe et al, 2002; Shaunak et al,
2004) with: (i) ultrapure S. minnesota LPS (25ng/ml, Invivogen)—
which is an MD-2 agonist; (ii) ultrapure Shigella LPS and Lipid A
(25ng/ml)—which are both MD-2 agonists; (iii) synthetic Lipid A
(100 ng/ml, Peptides International)—which is an MD-2 agonist and
(iv) LPS-RS (2.5mg/ml, Invivogen {i.e. 100-fold of the LPS concentration
used}) which is the diphosphoryl Lipid A from R. sphaeroides, and
which has been reported to be an MD-2 antagonist in TLR4-
transfected cells (Kutuzova et al, 2001).EMBO Mol Med (2012) 4, 866–881
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were constructed and cultured as previously described (West et al,
2005), and ultrapure LPS was also prepared from each strain. The
bacteria were cultured with human monocytes at a multiplicity of
infection of 10 for 1h followed by gentamicin for 2h. Anti-TLR4
antibody (HTA125) and protein EIAs were from eBioscience.
in vivo biology
Animal studies were performed under a French Ministry of Agriculture
licence for animal experimentation no 75-305. They took account of
the 3Rs of replacement, reduction and refinement, and were
performed in accordance with EU laws and regulations.
Ligated ileal loop segments of 5 cm with a Peyer’s patch were
surgically created in 1 h in New Zealand White rabbits (Oryctolagus
cuniculus) weighing 2.4–2.7 kg as previously described (Perdomo et al,
1994; Schnupf & Sansonetti, 2012). Typically, four ligated loops with
Peyer’s patches could be created in each rabbit. Wild-type S. flexneri
(M90T) in exponential phase growth (107 bacteria) were used to infect
each loop, endotoxin free (<0.06 EU/ml) DG added, and the abdomen
closed. The DG dose range was 0.1–50mg/loop in 1ml normal saline.
Rabbits were culled at 12 h for the PAMAM-DG experiments and at
18 h for the PETIM-DG experiments. Tissues were harvested for
histology [haematoxylin–eosin (H&E) and immuno-histochemistry],
and RNA using TriReagent. Loop fluid bacterial titres were determined
using Congo red plates.
The specialized epithelial cells overlying the lymphoid follicles called
Peyer’s patches are the first to be damaged in an infectious diarrhoea.
Mild gut wall damage was histologically defined as an intact epithelial
lining, minimal goblet cell depletion and a slight increase in the
number of neutrophils and lymphocytes in the surface epithelium and
lamina propria. Severe gut wall damage was histologically defined as a
destroyed surface epithelium, severe goblet cell depletion and a
marked increase in the number of neutrophils and lymphocytes in the
crypt epithelium and lamina propria (Islam et al, 1994; Islam &
Christensson, 2000; Islam et al, 2001; Raqib et al, 1994; Schnupf &
Sansonetti, 2012).
Design and construction of human and rabbit multi-gene
quantification plasmids for RT-PCR
messenger RNA quantification was performed by real-time PCR using
custom made human and rabbit quantification multi-gene plasmid
standards based upon methods and primer pairs as previously
described (Corware et al, 2011; Schnupf & Sansonetti, 2012; Shaunak
et al, 2004). Using this approach to quantitative RT-PCR, it was
possible to reliably and reproducibly identify twofold changes in
absolute mRNA copy number.
For the human multi-gene quantification plasmid, cDNA was made from
human monocytes treated with LPS (25ng/ml) for 3h. This induced
expression of otherwise low copy number chemokine and cytokine
mRNA transcripts. The cDNA was amplified by PCR using the human
primer pairs shown in Supplementary Table S1. A single human multi-
gene plasmid was made by sequential ligation and cloning of the
authenticated (by sequencing) PCR amplified products of b-actin, HPRT,
interferon-1b, interferon-g, IL-2, IL-6, IL-8, MIF, MIP-2a, MIP-1a (CCL3),
MIP-1b (CCL4), chemokine (C-C motif) ligand 5 (CCL5) and TNF-a into a
pGEM-TA (Promega) vector. The plasmid was sequenced to confirm its
identity and linearized with SacII.EMBO Mol Med (2012) 4, 866–881For the rabbit multi-gene quantification plasmids, cDNA was made
from the Peyer’s patches of Shigella infected rabbits. This induced
expression of otherwise low copy number chemokine and cytokine
mRNA transcripts. The cDNA was amplified by PCR using the rabbit
primer pairs shown in Supplementary Table S1. Two multi-gene
plasmid standards were constructed by ligation of the amplified and
authenticated (by sequencing) PCR products as described above. The
first plasmid contained GAPDH, IL-6, IL-8, MIP-1b (CCL4) and TNF-a
cloned into a TOPO4 (Invitrogen) vector that was linearized with NotI.
The second multi-gene plasmid contained HPRT, interferon-1b,
interferon-g, IL-12 p35, IL-12 p40 and IL-10 cloned into a pGEM-TA
vector and linearized with NotI. All other genes studied were cloned as
individual plasmids into cloning vectors pGEM TA, TOPO4 or pDrive
(Qiagen) and the amplified target gene number normalized using the
‘housekeeping’ HPRT reference gene.
Sample extraction and quantitative RT-PCR for mRNA expression
All samples were lysed with Tri-Reagent (Sigma) for RNA extraction.
For the rabbit tissue based samples, 1ml aliquots of Tri-Reagent
lysates were centrifuged in 2ml Max Tract tubes (Qiagen) at
12,000g for 10min, the aqueous phase above the wax barrier
removed, and the RNA precipitated as per the manufacturer’s
instructions. For tissue culture derived samples, the Max Tract tube
step was omitted. Eight hundred ng of purified RNA was then
reverse transcribed with a QuantiTect RT kit (Qiagen) which
incorporated a DNAse digestion step. The cDNAs were then diluted
1:4 with RNAse free water.
Standard curves were generated by serial 10-fold dilutions of 10 to
107 copies of the relevant plasmid in water containing 5 ng/ml
Lambda DNA. Triplicate 2ml aliquots of sample cDNA and 2ml
aliquots of each of the standard curve dilutions were amplified with
each gene specific primer pair in Jumpstart Sybr Green mix (Sigma) in
the same PCR run in a Corbett Research Rotor-Gene 3000 machine.
The fluorescence acquisition temperature was set at 5–78C below
the melting temperature of each amplified product in order to
eliminate any signal from primer-dimers. The authenticity of each
amplified product was confirmed by performing a melt curve
analysis at the end of each PCR run.
The absolute target copy number for each gene studied was then
normalized using the HPRT gene as the reference ‘housekeeping’ gene,
and the result expressed as the absolute copy number of target gene
mRNA per 105 absolute HPRT copy number. When the result was
expressed as a percentage change against control, the absolute target
gene number for both genes was first normalized using the HPRT
reference gene copy number and the percentage change then calculated.
Statistics
Graphpad Prism software and a two-tailed Mann–Whitney test were
used for data analysis.Author contributions
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